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Abstract
Strategies to prevent early-onset sepsis (EOS) have led to a substantial decline in many countries. However, one of
the most controversial topics in neonatology is the management of asymptomatic full-term and late preterm
neonates at risk for EOS, and guidelines lack substantial consensus regarding this issue. A strategy for managing
neonates, entirely based on serial physical examinations, has been developed in two Italian regions. This strategy
seems safe, while reducing laboratory tests and unnecessary antibiotics. In the current commentary we provide
area-based data concerning the prevention of EOS in 2 northern Italian regions, and we detail the results of their
strategy for managing healthy-appearing newborns at risk for EOS.
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Background
Group B streptococcus (GBS) remains a leading cause
of early-onset sepsis (EOS, the disease occurring at age
0–6 days) [1]. Intrapartum antibiotic prophylaxis (IAP)
is the mainstay of prevention. At the time the first
CDC guidelines were issued in the USA during the
‘90s, cases of GBS-EOS were 3–4/1000 live births, but
currently they have declined to fewer than 0.25 per
1000 live birth [2]. However, guidelines for preventing
EOS lack substantial consensus regarding the manage-
ment of asymptomatic neonates at-risk for EOS. [2]
CDC guidelines recommend full diagnostic evaluation
and antibiotic therapy if signs of sepsis; limited evalu-
ation and antibiotic therapy in case of chorioamnioni-
tis; limited evaluation and observation if preterm birth
of prolonged rupture of membrane [1]. However, ancil-
lary laboratory tests have poor predictive value, and
may result in medical intervention for a large number
of uninfected infants [2]. A less invasive approach, en-
tirely based on serial clinical observations is now rec-
ommended in some European guidelines [3].
Main text
The recent national survey [4] shows that the
screening-based strategy is largely prevalent and proto-
cols in most centers are consistent with the CDC guide-
lines [1]. However, differences in GBS EOS sepsis occur
among Northern, Central and Southern regions. Further-
more, 75% of respondent neonatal units would obtain la-
boratory testing and 91% would administer empirical
antibiotics to full-term and preterm neonates exposed to
inadequate IAP, although asymptomatic [4]. This prac-
tice is not consistent with the CDC guidelines [1]. Italian
epidemiological data, on which to inform recommenda-
tions, are still insufficient. Furthermore there is no na-
tional laboratory-based surveillance system to tracking
serotypes, incidence rates of GBS-EOS, and the impact
of perinatal prevention interventions. Nevertheless,
area-based data have been obtained prospectively in two
northern Italian regions (Emilia-Romagna and
Friuli-Venzia Giulia) [5–10]. In Emilia-Romagna, a
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detailed information has been obtained during a 9 years
GBS surveillance period [6–10]. In both regions the pre-
vention of EOS relies upon local protocols, mostly con-
sistent with vagino-rectal screening and IAP according
to the CDC guidelines (Table 1).
Colonization ranges from 18 to 21% of pregnant
women, [5–10] and up to ~1/3 of them receive IAP.
Area-based data on GBS-EOS is available in
Emilia-Romagna (from 2003 onwards), and in
Friuli-Venezia Giulia (from 2005 to 2006). In both re-
gions incidence rates of GBS-EOS are currently under
0.25/1000 live births.
The case fatality ratio among full-term neonates is close
to zero. Both regions recommend no laboratory tests or
empirical antibiotics for neonates at-risk for EOS who
have an entirely normal physical exam [5, 6]. Their strat-
egy is based on serial physical examinations (SPE), i.e. on
vital signs that can be easily detected by medical and
non-medical staff. Each examiner fills in and signs at
standard intervals a sheet (included in the medical re-
cords) detailing general wellbeing, reactivity, spontaneous
motility, skin colour (including perfusion) and respiratory
signs. Seven (at age 3–6–12–18-24–36–48 h) or 12 visits
(at 1, 2, 4, 8, 12, 16, 20, 24, 30, 36, 42, and 48 h) are rec-
ommended in Emilia-Romagna and Friuli-Venezia-Giulia
respectively. All neonates are left with their own mothers
(rooming in), without being admitted to NICU or level II
nursery. Every evaluation requires a maximum of 1 to
2 min; nursing staff and midwives give notification to cli-
nicians when signs of illness develop.
During 2005–2006 Cantoni and co-workers compared
in Friuli Venezia Giulia 7628 full term neonates managed
with the standard approach to 7611 full term newborns
managed through the SPE strategy. [5] Sepsis screenings
and antibiotic treatments decreased significantly (from 6.3
to 0.5%, p < 0.01 and from 1.2 to 0.5%, p < 0.01 respect-
ively). No treatment was delayed. Furthermore, a study
carried out in a single centre of Emilia-Romagna re-
ported significant reduction of laboratory tests (from
11.6 to 1.6%, p < 0.01) and empirical antibiotics (from
2.8 to 0.6%, p < 0.01) [11]. In a further retrospective
study carried out in 3 NICUs of Emilia-Romagna, 2092
full-term and late preterm neonates were managed with
SPEs. Among 632 initially asymptomatic neonates
at-risk for EOS, only 3% were evaluated (0.9% of the en-
tire cohort) and only 1.1% (0.3% of the entire cohort)
were given empirical antibiotics. No cases of EOS were
missed, and no neonates had complications or a worse
outcome due to this strategy [12]. Although evidences
supporting the SPE based prevention in regions with
higher rates of GBS EOS are still lacking, we are con-
vinced that it could be similarly effective.
Discussion
Here we resume and compare area-based data from 2
Italian regions. They add information for assisting health-
care providers in planning national strategies. As preterm
neonates younger than 34 weeks’ gestation need special
care in NICUs, we focused on late preterm (34–36 weeks’
gestation) and full-term (≥37 weeks’ gestation) neonates,
that account for over 90% of total deliveries and are man-
aged in all birthing centers across country. The recent na-
tional survey [4] has shown that great resources are
poored into prevention of EOS, and often are given un-
necessary antibiotics. Ancillary laboratory tests currently
available are low predictive for asymptomatic neonates
and have insufficient accuracy for guiding the decision as
to whether neonates should be treated with antibiotics [2].
Table 1 Colonization rates and IAP in Emilia-Romagna and Friuli-Venezia Giulia
Emilia-Romagna [6–10] Friuli-Venezia Giulia [5]
Years in study 2003–2005 2009–2012 2005–2006
Live births 112,933 146,682 16,394
Preterm deliveries (%) 7.3 7.4 7.7
Prevention strategy V-R screening V-R screening V-R screening
Rates of prenatal screening (%) 86.6 93.2 § 89.0 §
Rates of vagino-rectal cultures (%) 42.7 90.4 § 88.6
Rates of maternal GBS colonization (%) 18.1 § 21.4 § 19.8
Overall rates of IAP (%) 28.7 32.0 ND
Rates of IAP to women with GBS colonization (%) 92.6 90.2 83%
Prevalence of risk factors for EOS (%) ND 20.1 22.1
GBS-EOS (cases/1000 live births) 0.25 0.15 0
GBS-EOS mortality (cases/1000 live births) 0.02 0.01 0
GBS-EOS mortality in full-term neonates, (cases/1000 live births) 0 0 0
EOS early-onset sepsis, GBS group B streptococcus, IAP intrapartum antibiotic prophylaxis, V-R vaginorectal
§ refers to full term deliveries
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A recent survey carried out in in Europe, North America,
and Australia have shown that 14% of full-term neonates
worldwide are evaluated annually for EOS. Furthermore,
8% of them are treated with antibiotics, although EOS is
confirmed only in 0.1% [13]. The large number of unin-
fected newborns being evaluated and treated with antibi-
otics may lead to maternal/infant separation and longer
length of stay. Furthermore, antibiotics can increase the
risk of resistant pathogens and alter the neonatal micro-
biome, with risks of health problems in later life (allergies,
diabetes, and inflammatory bowel diseases) [13, 14]. How-
ever, many infants with mild illness can be observed safely
without treatment (unless clinical signs worsen or fail to
improve), as they become asymptomatic over the first 6 h.
Finally, in a recent and very comprehensive review on risks
and benefits of evolving rule-out sepsis practices, [15]
Hooven and co-workers estimate (number needed to harm,
NNH) the potential complications of strategies for
managing neonates at risk for EOS. They compare the
rare risks of developing severe symptoms of EOS
(NNH = 1610) and the more common risks of infiltrate
after i.v. infusion (NNH = 7) or delayed breastfeeding
(NNH = 2.9). Investigators conclude that there is strong
evidence to support observation-based approaches for
managing neonates at risk for EOS.
Conclusion
The SPEs strategy has proven sensitive for timely detec-
tion of all cases of EOS, not only for GBS sepsis. By pro-
viding strong assurance that frequent examinations
actually are performed, this strategy seems safe, reliable
and easy to perform. Strategies reducing neonatal
hospitalization during the first week life, respecting the
bonding of mother and infant, and minimising unneces-
sary antibiotics must be taken into consideration.
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